SERMs and SARMs: Detection of their activities with yeast based bioassays

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 1-2, 2010, Pages 85-92

  Bovee, Toine F H ^a   Thevis, Mario ^b   Hamers, Astrid R M ^a   Peijnenburg, Ad A C M ^a   Nielen, Michel W F ^a   Schoonen, Willem G E J ^c  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Agonists; Androgenic activity; Antagonists; Estrogenic activity; In vitro bioassays; Metabolism

Indexed keywords

16BETA HYDROXYSTANOZOLOL; 5ALPHA ANDROSTANE 3BETA OL 17ALPHA DIOL; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYPROTERONE ACETATE; DESOXYMETHYLTESTOSTERONE; DEXAMETHASONE; EPIANDROSTERONE; ESTRADIOL; ESTRADIOL 11 BETA 3 CYCLOPROPYLIDENEPROPYL; ESTRADIOL 11 BETA BUTYL; ESTRADIOL 11 BETA HYDROXYPENTYL; ESTRADIOL 11 BETA N YL; ESTRADIOL 11 BETA PENTENYL; ESTRADIOL 11 BETA PENTYL; ESTROGEN; ETHINYLESTRADIOL; ETIOCHOLANOLONE; FLUOXYMESTERONE; FLUTAMIDE; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYFLUTAMIDE; METHYLTESTOSTERONE; NILUTAMIDE; OXANDROLONE; PRASTERONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; HORMONE ACTION; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION INITIATION; YEAST;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; BIOLOGICAL ASSAY; CHO CELLS; CRICETINAE; CRICETULUS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GREEN FLUORESCENT PROTEINS; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, ANDROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUBSTANCE ABUSE DETECTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; YEASTS;

EID: 72449170947     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.10.007     Document Type: Article

References (38)

1. Coelingh Bennink H.J. Are all estrogens the same?. Maturitas 47 (2004) 269-275
2. Bross R., Storer T., and Bashin S. Aging and muscle loss. Trends Endocrinol. Metabol. 10 (1999) 194-198
3. Muller M., Grobbee D.E., Thijssen J.H.H., Van den Beld A.W., and Van der Schouw Y.T. Sex hormones and male health: effects on components of the frailty syndrome. Trends Endocrinol. Metabol. 14 (2003) 289-296
4. Davis S.R. The therapeutic use of androgens in women. J. Steroid Biochem. Mol. Biol. 69 (1999) 177-184
5. Lopez F.J. New approaches to the treatment of osteoporosis. Curr. Opin. Chem. Biol. 4 (2000) 383-393
6. Doherty T.J. Aging and sarcopenia. J. Appl. Physiol. 95 (2003) 1717-1727
7. Chodak G., Gomella L., and De Phung H. Combined androgen blockade in advanced prostate cancer: looking back to move forward. Clin. Genitourin. Cancer 5 (2007) 371-378
8. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008) 331-340
9. Plouffe Jr. L. Selective estrogen receptors modulators (SERMs) in clinical practice. J. Soc. Gynecol. Investig. 7 (2000) 38-46
10. Arun B., Anthony M., and Dunn B. The search for the ideal SERM. Expert Opin. Pharmacother. 3 (2002) 681-691
11. Leblanc K., Sexton E., Parent S., Belanger G., Dery M.C., Boucher V., and Asselin E. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int. J. Oncol. 30 (2007) 477-487
12. Kolvenbag G.J., and Blackledge G.R. Worldwide activity and safety of bicalutamide: a summary review. Urology 47 (1996) 70-84
13. Schellhammer P.F., Sharifi R., Block N.L., Soloway M.S., Venner P.M., Patterson A.L., Sarosdy M.F., Vogelzang N.J., Chen C.Y., and Kolvenbag G.J.C.M. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Urology 45 (1995) 745-752
14. Chen F., Rodan G.A., and Schmidt A. Development of selective androgen receptor modulators and their therapeutic applications. Zhonghua Nan Ke Xue 8 (2002) 162-168
15. Thevis M., Kamber M., and Schänzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun. Mass Spectrom. 20 (2006) 870-876
16. Miner J.N., Chang W., Chapman M.S., Finn P.D., Hong M.H., López F.J., Marschke K.B., Rosen J., Schrader W., Turner R., Van Oeveren A., Viveros H., Zhi L., and Negro-Vilar A. An orally active selective androgen receptor modulator is efficious on bone, muscle, and sex function with reduced impact on prostate. Endocrine 148 (2007) 363-373
17. Bovee T.F.H., Bor G., Heskamp H.H., Lasaroms J.J.P., Sanders M.B., and Nielen M.W.F. Validation and application of a yeast bioassay for screening androgenic activity in calf urine and feed. Anal. Chim. Acta 637 (2009) 225-234
18. Bovee T.F.H., Helsdingen J.R., Rietjens I.M.C.M., Keijer J., and Hoogenboom L.A.P. Rapid yeast estrogen bioassays stably expressing human estrogen receptors α and β, and green fluorescent protein: a comparison of different compounds with both receptor types. J. Steroid Biochem. Mol. Biol. 91 (2004) 99-109
19. Bovee T.F.H., Schoonen W.G.E.J., Hamers A.R.M., Jorge-Bento M., and Peijnenburg A.A.C.M. Screening of synthetic and plant-derived compounds for (anti)estrogenic and (anti)androgenic activities. Anal. Bioanal. Chem. 390 (2008) 1111-1119
20. Bovee T.F.H., Lommerse J.P.M., Peijnenburg A.A.C.M., Antunes-Fernandes E., and Nielen M.W.F. A new highly androgen specific yeast biosensor, enabling optimisation of (Q)SAR model approaches. J. Steroid Biochem. Mol. Biol. 108 (2008) 121-131
21. Thevis M., Kohler M., Maurer J., Schlörer N., Kamber M., and Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Commun. Mass Spectrom. 21 (2007) 3477-3486
22. Schoonen W.G.E.J., Dijkema R., De Ries R.J.H., Wagenaars J.L., Joosten J.W.H., De Gooyer M.E., Deckers G.H., and Kloosterboer H.J. Human progesteron receptor A and B isoforms in CHO cells II comparison of binding, transactivation and ED50 values of several synthetic (anti)progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats. J. Steroid Biochem. Mol. Biol. 64 (1998) 157-170
23. Sonneveld E., Riteco J.A.C., Jansen H.J., Pieterse B., Brouwer A., Schoonen W.G., and Van der Burg B. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 89 (2006) 173-187
24. Schoonen W.G.E.J., Westerink W.M.A., and Horbach G.J. High-throughput screening for the analysis of in vitro toxicity. In: Luch A. (Ed). Molecular, Clinical and Environmental Toxicology vol. 1 (2009), Birkhäuser Publishing, Basel, Switzerland 401-439 chapter 14
25. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: 3D structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21 (2000) 381-388
26. Milligan S., Kalita J., Pocock V., Heyerick A., De Cooman L., Rong H., and De Keukeleire D. Oestrogenic activity of the hop phyto-estrogen, 8 prenylnaringenin. Reproduction 123 (2002) 235-242
27. Morito K., Hirose T., Kinjo J., Hirakawa T., Okawa M., Nohara T., Ogawa S., Inoue S., Muramatsu M., and Masamune Y. Interaction of phytoestrogens with estrogen receptors α and β. Biol. Pharm. Bull. 24 (2001) 351-356
28. Bovee T.F.H., and Pikkemaat M.G. Invited review: bioactivity-based screening of antibiotics and hormones. J. Chrom. A1216 (2009) 8035-8050
29. Bohl C.E., Wu Z., Miller D.D., Bell C.E., and Dalton J.T. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 282 (2007) 13648-13655
30. Scherrer R., Louden L., and Gerhardt P. Porosity of the yeast cell wall and membrane. J. Bacteriol. 118 (1974) 534-540
31. De Nobel J.G., and Barnett J.A. Passage of molecules through yeast cell walls: a brief essay-review. Yeast 7 (1991) 313-323
32. Van der Rest M.E., Kamminga A.H., Nakano A., Anraku Y., Poolman B., and Konings W.N. The plasma membrane of Saccharomyces cerevisae: structure, function, and biogenesis. Microbiol. Rev. 59 (1995) 304-322
33. Houtman C.J., Sterk S.S., Van de Heijning M.P., Brouwer A., Stephany R.W., Van der Burg B., and Sonneveld E. Detection of anabolic androgenic steroid abuse in doping control using mammalian reporter gene assays. Anal. Chim. Acta 637 (2009) 247-258
34. Van Oeveren A., Motamedi M., Martinborough E., Zhao S., Shen Y., West S., Chang W., Kallel A., Marschke K.B., López F.J., Negro-Vilar A., and Zhi L. Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg. Med. Chem. Lett. 17 (2007) 1527-1531
35. Hodgson M.C., Astapova I., Hollenberg A.N., and Balk S.P. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 67 (2007) 8388-8395
36. Gao W., Wu Z., Bohl C.E., Yang J., Miller D.D., and Dalton J.T. Characterization of the in vivo metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations. Drug Metabol. Dispos. 34 (2006) 243-253
37. Kuuranne T., Leinonen A., Schänzer W., Kamber M., Kostiainen R., and Thevis M. Arylpropionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metabol. Dispos. 36 (2008) 571-581
38. Wu D., Wu Z., Yang J., Nair V.A., Miller D.D., and Dalton J.T. Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metab. Dispos. 34 (2006) 483-494